Lower Rates of Hospitalization for Heart Failure and All-Cause Death in New Users of SGLT-2 Inhibitors Versus Other Glucose Lowering Drugs – Real World Data from Six Countries and More Than 300,000 Patients: the CVD-REAL Study

Mar-17

AUTHORS : Dr Mikhail Kosiborod, Saint Luke’s Mid America Heart Institute, 4401 Wornall Rd, Kansas City, MO 64111 – E-mail: mkosiborod@saint-lukes.org – Profile: https://doctors.saintlukeskc.org/provider/Mikhail+N+Kosiborod/1458591 also read article: https://www.saintlukeskc.org/about/news/saint-lukes-innovation-week-profile-dr-mikhail-kosiborod

JOURNAL : Journal of the American College of Cardiology

REFERENCE: 69(11)

DOI :

Lower Rates of Hospitalization for Heart Failure and All-Cause Death in New Users of SGLT-2 Inhibitors Versus Other Glucose Lowering Drugs – Real World Data from Six Countries and More Than 300,000 Patients: the CVD-REAL Study

More publications

Comparative effect of aspirin versus clopidogrel monotherapy on incident type 2 diabetes in patients with atherosclerotic cardiovascular diseases: A target trial emulation study

Postoperative Weight Loss After Antiobesity Medications and Revision Risk After Joint Replacement

Comparative effectiveness and prescribing trends of modified release versus immediate release indapamide in patients with hypertension: cohort study